California Institute for Regenerative Medicine
State-funded agency established to accelerate stem cell, regenerative medicine, and gene therapy research by funding projects across the research pipeline, building research infrastructure, supporting workforce development, and enabling patient access and clinical translation through grants, partnerships, and data infrastructure.
Industries
Nr. of Employees
small (1-50)
California Institute for Regenerative Medicine
San Francisco, California, United States, North America
Products
Basic Biology Awards (I & II)
Competitive awards to investigate fundamental mechanisms of stem cell biology and cellular differentiation to support future translational efforts.
Disease Team Research Awards
Large, milestone-driven awards for multidisciplinary teams focused on advancing therapies to IND readiness and early clinical testing.
R&D data explorer and clinical trial coordination platform
Data infrastructure tools to share award-generated data and coordinate clinical trial information and sites across funded programs.
Basic Biology Awards (I & II)
Competitive awards to investigate fundamental mechanisms of stem cell biology and cellular differentiation to support future translational efforts.
Disease Team Research Awards
Large, milestone-driven awards for multidisciplinary teams focused on advancing therapies to IND readiness and early clinical testing.
R&D data explorer and clinical trial coordination platform
Data infrastructure tools to share award-generated data and coordinate clinical trial information and sites across funded programs.
Services
Administers grant programs for Discovery, Preclinical, Translational, Clinical, Education, and Infrastructure projects delivered through RFAs and milestone-driven awards.
Provides centralized award administration, financial oversight, compliance monitoring, and grant management systems to manage funded projects.
Develops data-sharing initiatives and maintains platforms to make funded research data and clinical trial information discoverable and to support site coordination.
Awards internships, training grants, and educational programs to build a pipeline of scientists and technicians in regenerative medicine.
Implements programs to improve patient access to clinical trials and provide support services for patients navigating trial participation.
Builds and manages partnerships with industry, investors, and other funders to support commercialization and translational pathways for funded projects.
Administers grant programs for Discovery, Preclinical, Translational, Clinical, Education, and Infrastructure projects delivered through RFAs and milestone-driven awards.
Provides centralized award administration, financial oversight, compliance monitoring, and grant management systems to manage funded projects.
Develops data-sharing initiatives and maintains platforms to make funded research data and clinical trial information discoverable and to support site coordination.
Awards internships, training grants, and educational programs to build a pipeline of scientists and technicians in regenerative medicine.
Implements programs to improve patient access to clinical trials and provide support services for patients navigating trial participation.
Builds and manages partnerships with industry, investors, and other funders to support commercialization and translational pathways for funded projects.
Expertise Areas
- Stem cell and regenerative medicine research
- Cell and gene therapy development
- Clinical trial funding and coordination
- IND/IDE regulatory support and preparation
Key Technologies
- Stem cell biology
- Induced pluripotent stem cells (iPSC) methodologies
- Cell and gene therapy development
- T cell engineering and CAR-T platforms
News & Updates
Regular public meetings of the governing board, Grants Working Group, and subcommittees to review applications and advise policy.
Blog posts and feature articles covering program updates, interviews, and research highlights in regenerative medicine.
Created in 2004 by California Proposition 71 with an initial funding allocation of $3 billion to support stem cell research and related infrastructure.
California Proposition 14 (2020) renewed and expanded funding, providing $5.5 billion for additional stem cell and regenerative medicine research programs and patient access initiatives.
Has funded and supported more than 100 cell and gene therapy clinical trials across multiple diseases and indications.
Regular public meetings of the governing board, Grants Working Group, and subcommittees to review applications and advise policy.
Blog posts and feature articles covering program updates, interviews, and research highlights in regenerative medicine.
Created in 2004 by California Proposition 71 with an initial funding allocation of $3 billion to support stem cell research and related infrastructure.
California Proposition 14 (2020) renewed and expanded funding, providing $5.5 billion for additional stem cell and regenerative medicine research programs and patient access initiatives.
Has funded and supported more than 100 cell and gene therapy clinical trials across multiple diseases and indications.